Lumida
/IRWD
⌘K
Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

IRWD
$3.86USD↓-0.26%-0.01 today

MARKET CAP

635.4M

P/E (TTM)

6.3x

FWD P/E

3.2x

DAY RANGE

$4 – $4

52W RANGE

$1
$6

AI Summary

Stalk
Sell NowHigh

IRWD remains in a Stage 4 decline with confirmed lower highs and lower lows under a bearish EMA regime. Price is trading below the down-sloping 9 and 21 EMAs and is now pulling back toward the 50 DMA without evidence of selling exhaustion or stabilization. The medium-term bias is bearish, permitting only sell-side engagement. Execution should focus on Sell Now into rallies to the 9/21 EMA resistance and recent horizontal levels.

  • ↑Linzess net sales $272.5m in Q1 2026, up 97% YoY.
  • ↑Apraglutide Phase 3 STARS-2 trial underway; peak sales forecast >$1B.
  • ↓Profitability under pressure from pricing cuts and rising costs.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a biotechnology company specializing in gastrointestinal therapies, particularly focusing on treatments for conditions such as irritable bowel syndrome (IBS) and short bowel syndrome (SBS). The company is known for its leading product, Linzess, and is making strides with its pipeline, especially in developing apraglutide for SBS. Positioned in a niche market that spans both gastrointestinal and rare diseases, Ironwood leverages its existing products while advancing innovative therapies aimed at improving patient outcomes.

Bull says

  • ↑Linzess net sales $272.5m in Q1 2026, up 97% YoY.
  • ↑Apraglutide Phase 3 STARS-2 trial underway; peak sales forecast >$1B.
  • ↑FDA cleared Linzess for pediatric IBS (ages 2–5), broadening market.
  • ↑$220.5m cash on hand supports operations and pipeline funding.
  • ↑Strong momentum and low short interest signal market confidence.
  • ↑High earnings yield and robust growth factors underpin valuation upside.

Bear says

  • ↓Profitability under pressure from pricing cuts and rising costs.
  • ↓~$300m debt by end-2026 may strain financial flexibility.
  • ↓~90% revenue tied to Linzess; any pricing or competition setback endangers earnings.
  • ↓Apraglutide faces competition from GATEX and generics on the horizon.
  • ↓Linzess patent expiry in 2029 threatens long-term growth trajectory.
  • ↓Weak profitability and negative revisions factors highlight elevated risk.

Investment themes with IRWD

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-08-2026bullish

Transcript signals

Bull points

  • In the first quarter, total revenue was $106.5 million. Gap net income was $40.8 million and adjusted EBITDA was $76.7 billion. We ended the first quarter of 2026 with $220.5 million of cash and cash equivalents on the balance sheet, as well as $105.8 million in accounts receivable, which we expect to collect prior to the June 15th convertible note maturity.
  • We are reiterating our 2026 guidance at this time. This includes LINZES U.S. net sales of between $1.125 and $1.175 billion. We expect adjusted EBITDA of greater than $300 million.
  • 2026 is off to a great start, with Strongwind's best performance, a significantly improved financial position relative to 2025, and the impending initiation of the STARS-2 confirmatory trial. We continue to make progress on executing on our strategic priorities, as we strive to redefine the standard of care for patients living with GI and rare diseases.
Read full transcript analysis ›